An anonymous director reports
AETERNA ZENTARIS ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING
Aeterna Zentaris Inc. has priced a public offering of 26,666,666 units at a price to the public of 45 cents per unit for gross proceeds of $12-million before deducting placement agent fees and other offering expenses payable by the company. Each unit contains one common share (or common share equivalent) and one common warrant to purchase one common share. The common shares (or common share equivalents) and common share warrants included in the units can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about July 7, 2020, subject to satisfaction customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Each common share warrant has an exercise price of 45 cents per share, is exercisable immediately and will expire five years from the date of issuance.
The company intends to use the net proceeds of this offering for general corporate purposes, which include, among other purposes, the financing of a pediatric clinical trial in the European Union and the United States for Macrilen (macimorelin), the investigation of further therapeutic uses of macimorelin, and the expansion of pipeline development activities.
The securities described herein are being offered by Aeterna Zentaris pursuant to an effective registration statement on Form F-1 (file No. 333-232935) filed with the Securities and Exchange Commission (SEC) and declared effective on July 1, 2020. The offering is being made only by means of a prospectus forming part of the effective registration statement. The final terms of the offering will be disclosed in a final prospectus to be filed with the SEC and made available on the SEC's website. Electronic copies of the final prospectus, when available, may also be obtained by contacting H.C. Wainwright & Co., 430 Park Ave., third floor, New York, N.Y., 10022, by telephone at 646-975-6996 or by e-mail at
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company, commercializing and developing therapeutics and diagnostic tests. The company's lead product, Macrilen (macimorelin), is the first and only U.S. Food and Drug Administration- and European Commission-approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen is currently marketed in the United States through a licence agreement with Novo Nordisk, and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.